<DOC>
	<DOCNO>NCT01218646</DOCNO>
	<brief_summary>The aim study evaluate prototype quadrivalent influenza vaccine ( QIV ) , license 2010-2011 trivalent influenza vaccine ( TIV ) contain primary B strain , investigational TIV contain alternate B strain adult subject . Primary Objective : - To demonstrate non-inferiority antibody responses QIV compare license 2010-2011 TIV ( contain primary B strain ) investigational TIV ( contain alternate B strain ) assess geometric mean titer ( GMT ) ratios four virus strain separately among subject 65 year age old Observational Objective : - To describe safety profile TIV among subject 18 year age old QIV subject 65 year old , assess solicit injection site systemic adverse event ( AEs ) collect 7 day post-vaccination , unsolicited adverse event collect 21 day post-vaccination , adverse event special interest serious adverse event ( SAEs ) collect Visit 1 Visit 2 .</brief_summary>
	<brief_title>Study Quadrivalent Influenza Vaccine Among Adults</brief_title>
	<detailed_description>All participant receive single dose assign vaccine Visit 1 . They follow safety immunogenicity Day 21 post-vaccination ( Visit 2 )</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Subject 18 year age old day inclusion . Informed consent form ( ICF ) sign date . Able attend schedule visit comply trial procedure . For woman childbearing potential , use effective method contraception abstinence least 4 week prior first vaccination least 4 week postvaccination . Exclusion criterion : Known pregnancy , positive urine pregnancy test . Currently breastfeed child . History serious adverse reaction influenza vaccine . Receipt vaccine 4 week precede trial vaccination . Planned receipt vaccine Visit 1 Visit 2 . Participation another interventional clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first study vaccination course study . Receipt influenza vaccine since 01 August 2010 ( include 2009 H1N1 monovalent vaccine ) . Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine ( ) use trial vaccine contain substance . Receipt blood bloodderived product past 3 month , might interfere assessment immune response . Thrombocytopenia , bleed disorder , receipt anticoagulant contraindicate intramuscular vaccination . Any condition opinion Investigator would pose health risk subject enrol could interfere evaluation vaccine . Personal history GuillainBarr√© Syndrome ( GBS ) . Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) . Any chronic illness , opinion Investigator , well control may interfere trial conduct completion assessment adverse event . Known seropositivity human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C. Deprived freedom administrative court order , emergency setting , hospitalize involuntarily . Current alcohol drug use , opinion Investigator , might interfere ability comply trial procedure . Identified employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Quadrivalent Inactivated Influenza Vaccine</keyword>
	<keyword>Trivalent Inactivated Influenza Vaccine</keyword>
	<keyword>Influenza virus</keyword>
</DOC>